Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 53.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,455 shares of the company’s stock after selling 150,357 shares during the period. GSA Capital Partners LLP owned about 0.22% of Monte Rosa Therapeutics worth $989,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the period. American Century Companies Inc. grew its holdings in shares of Monte Rosa Therapeutics by 301.4% in the second quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after purchasing an additional 302,639 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in Monte Rosa Therapeutics during the 2nd quarter worth approximately $1,224,000. Bank of America Corp DE increased its stake in Monte Rosa Therapeutics by 941.1% during the 2nd quarter. Bank of America Corp DE now owns 271,164 shares of the company’s stock worth $1,223,000 after buying an additional 245,119 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock worth $1,652,000 after buying an additional 196,238 shares in the last quarter. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the transaction, the chief executive officer directly owned 618,937 shares in the company, valued at $14,538,830.13. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.90% of the stock is owned by company insiders.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ GLUE opened at $19.16 on Friday. The business has a 50-day moving average of $19.63 and a two-hundred day moving average of $12.96. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of 59.88 and a beta of 1.61. Monte Rosa Therapeutics, Inc. has a 1 year low of $3.50 and a 1 year high of $25.77.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price target (up previously from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Finally, Guggenheim raised their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.